Effect of Benralizumab on Airway Remodeling in Asthma

Inclusion Criteria: Healthy subjects * Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study. * Age higher than 18 years. * No prior history of any chronic respiratory disease including asthma. * No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema. * No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1. * Normal lung function with FEV1 \> 90%. Non-severe asthmatics subjects * • Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study. * Age higher than 18 years. * Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA), i.e. GINA steps 1, 2 or 3 (18). * Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment, or PC20 methacholine \< 16 mg/mL documented within 12 months prior to screening. * Documented blood eosinophils ≥300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1. Severe asthmatics subjects * • Written inform consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study. * Age higher than 18 years. * Diagnosis of severe asth…